Price Alert

Aligos Therapeutics Inc. (ALGS)

NASDAQ: ALGS · Real-Time Price · USD

10.07

-0.17 (-1.66%)

At close: Oct 03, 2025, 3:59 PM

10.07

0.00%

After-hours: Oct 03, 2025, 05:18 PM EDT

-1.66% (1D)

Bid	9.31
Market Cap	61.94M
Revenue (ttm)	3.17M
Net Income (ttm)	-74.18M
EPS (ttm)	-13.27
PE Ratio (ttm)	-0.76
Forward PE	-1.4
Analyst	Buy
Dividends	n/a

Ask	10.39
Volume	86,672
Avg. Volume (20D)	77,788.3
Open	10.18
Previous Close	10.24
Day's Range	9.61 - 10.18
52-Week Range	3.76 - 46.80
Beta	2.77
Ex-Dividend Date	n/a

About ALGS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALGS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALGS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Aligos Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+13.9%

Aligos Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

7 months ago

-19.55%

Aligos Therapeutics shares are trading lower after the company reported Q4 financial results and missed its EPS estimate.

News

4 weeks ago · zacks.com

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionabl...

1 month ago · zacks.com

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionabl...

2 months ago · zacks.com

Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $2.35. This compares to earnings of $0.75 per share a year ago.